Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome.
Docetaxel (Taxotere) is an anticancer agent used to treat a wide range of malignancies including breast, lung, and prostate cancer. In this report, we describe a patient with bilateral vision loss due to cystoid macular edema (CME) associated with docetaxel therapy. This report documents for the first time the optical coherence tomography (OCT) findings of CME despite the lack of leakage with flourescein angiography and its association with the Fluid Retention Syndrome (FRS). Successful management of CME with oral acetazolamide is also discussed.
Telander
David G
DG
Department of Ophthalmology, University of California, Davis, Sacramento, CA, USA.
Sarraf
David
D
D000086:Acetazolamide / Q000008:administration & dosage / Q000627:therapeutic use; D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000556:secondary; D004232:Diuretics / Q000008:administration & dosage / Q000627:therapeutic use; D000077143:Docetaxel; D004487:Edema / Q000139:chemically induced* / Q000188:drug therapy; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008269:Macular Edema / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D008875:Middle Aged; D043823:Taxoids / Q000009:adverse effects* / Q000627:therapeutic use; D041623:Tomography, Optical Coherence
D000970:Antineoplastic Agents; D004232:Diuretics; D043823:Taxoids; D000077143:Docetaxel; D000086:Acetazolamide